Day One Biopharmaceuticals, Inc. (DAWN)
NASDAQ: DAWN · IEX Real-Time Price · USD
14.85
+0.24 (1.64%)
At close: Apr 17, 2024, 4:00 PM
15.37
+0.52 (3.50%)
Pre-market: Apr 18, 2024, 7:13 AM EDT
DAWN Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for DAWN stock have an average target of 35.33, with a low estimate of 9.00 and a high estimate of 50. The average target predicts an increase of 137.91% from the current stock price of 14.85.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for DAWN stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 3 | 3 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $40 | Buy | Maintains | $40 | +169.36% | Mar 26, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $45 → $40 | Buy | Maintains | $45 → $40 | +169.36% | Feb 28, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $50 → $44 | Strong Buy | Maintains | $50 → $44 | +196.30% | Feb 27, 2024 |
| Oppenheimer | Oppenheimer | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Feb 27, 2024 |
| Wedbush | Wedbush | Buy Maintains $39 → $35 | Buy | Maintains | $39 → $35 | +135.69% | Nov 7, 2023 |
Financial Forecast
Revenue This Year
13.33M
Revenue Next Year
75.80M
from 13.33M
Increased by 468.62%
EPS This Year
-2.67
from -2.37
EPS Next Year
-2.05
from -2.67
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 25.2M | 156.4M | 496.8M | 696.3M | 924.0M |
| Avg | 13.3M | 75.8M | 252.8M | 490.5M | 605.7M |
| Low | 3.3M | 14.8M | 117.2M | 256.1M | 408.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 1,072.8% | 555.4% | 175.5% | 88.4% |
| Avg | - | 468.6% | 233.5% | 94.0% | 23.5% |
| Low | - | 11.0% | 54.6% | 1.3% | -16.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.38 | -1.27 | 0.21 | 2.78 | 4.55 |
| Avg | -2.67 | -2.05 | -0.60 | 1.59 | 2.71 |
| Low | -2.83 | -2.72 | -1.50 | -0.29 | 0.98 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 185.3% |
| Avg | - | - | - | - | 69.8% |
| Low | - | - | - | - | -38.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.